Patents Assigned to FibroGen, Inc.
  • ENHANCED ERYTHROPOIESIS AND IRON METABOLISM
    Publication number: 20240182424
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Application
    Filed: May 15, 2023
    Publication date: June 6, 2024
    Applicant: FibroGen, Inc.
    Inventors: Stephen J. KLAUS, Christopher J. MOLINEAUX, Thomas B. NEFF, Volkmar GUENZLER-PUKALL, Robert C. STEPHENSON, Todd W. SEELEY, Ingrid LANGSETMO PAROBOK
  • CONNECTIVE TISSUE GROWTH FACTOR ANTIBODIES
    Publication number: 20240076364
    Abstract: The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.
    Type: Application
    Filed: December 20, 2022
    Publication date: March 7, 2024
    Applicant: FibroGen, Inc.
    Inventors: Al Y. LIN, Thomas B. NEFF, Noelynn A. OLIVER, William R. USINGER, Qingjian WANG, David A. YEOWELL
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 11680047
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erythropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: June 20, 2023
    Assignee: FibroGen, Inc.
    Inventors: Stephen J. Klaus, Al Y. Lin, Thomas B. Neff, Volkmar Guenzler-Pukall, Qingjian Wang, Lee A. Flippin, Michael P. Arend
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 11680048
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: June 20, 2023
    Assignee: FibroGen, Inc.
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Robert C. Stephenson, Todd W. Seeley, Ingrid Langsetmo Parobok
  • METHODS FOR TREATMENT OF MOTOR NEURON DISEASES
    Publication number: 20230019602
    Abstract: The invention relates to methods and agents useful for treating motor neuron diseases (MNDs), in particular, amyotrophic lateral sclerosis (ALS). Methods and agents for treating various physiological and pathological conditions associated with motor neuron diseases are also provided.
    Type: Application
    Filed: March 7, 2022
    Publication date: January 19, 2023
    Applicant: FibroGen, Inc.
    Inventors: Enrique BRANDAN, David GONZALEZ
  • METHODS FOR TREATING IDIOPATHIC PULMONARY FIBROSIS
    Publication number: 20220151581
    Abstract: The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IPF) by administering anti-CTGF antibodies. Methods for prognosing individuals with IPF are also provided.
    Type: Application
    Filed: January 27, 2022
    Publication date: May 19, 2022
    Applicant: FibroGen, Inc.
    Inventors: Seth PORTER, John L STAUFFER
  • Methods for treatment of motor neuron diseases
    Patent number: 11299537
    Abstract: The invention relates to methods and agents useful for treating motor neuron diseases (MNDs), in particular, amyotrophic lateral sclerosis (ALS). Methods and agents for treating various physiological and pathological conditions associated with motor neuron diseases are also provided.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: April 12, 2022
    Assignee: FIBROGEN, INC.
    Inventors: Enrique Brandan, David Gonzalez
  • Nitrogen-containing heteroaryl compounds and methods of use thereof
    Patent number: 11229637
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: January 25, 2022
    Assignee: FibroGen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE
    Publication number: 20210369702
    Abstract: The present invention provides methods for treating anemia in a subject having kidney failure by administering a compound that inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase.
    Type: Application
    Filed: August 5, 2021
    Publication date: December 2, 2021
    Applicant: FibroGen, Inc.
    Inventors: Stephen J. KLAUS, Al Y. LIN, Thomas B. NEFF, Qingjian WANG, Volkmar GUENZLER-PUKALL, Lee A. FLIPPIN, Michael P. AREND, Alex MELEKHOV
  • CONNECTIVE TISSUE GROWTH FACTOR ANTIBODIES
    Publication number: 20210230259
    Abstract: The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.
    Type: Application
    Filed: September 8, 2020
    Publication date: July 29, 2021
    Applicant: FibroGen, Inc.
    Inventors: Al Y. LIN, Thomas B. NEFF, Noelynn A. OLIVER, William R. USINGER, Qingjian WANG, David A. YEOWELL
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 10927081
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: February 23, 2021
    Assignee: FIBROGEN, INC.
    Inventors: Stephen J Klaus, Al Y. Lin, Thomas B. Neff, Volkmar Guenzler-Pukall, Qingjian Wang, Lee A. Flippin, Michael P. Arend
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 10894774
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: January 19, 2021
    Assignee: FIBROGEN, INC.
    Inventors: Stephen J. Klaus, Christopher J Molineaux, Thomas B Neff, Volkmar Guenzler-Pukall, Robert C. Stephenson, Todd W. Seeley, Ingrid Langsetmo Parobok
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 10882827
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erythropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: January 5, 2021
    Assignee: FIBROGEN, INC.
    Inventors: Stephen J Klaus, Christopher J Molineaux, Thomas B Neff, Volkmar Guenzler-Pukall, Robert C Stephenson, Todd W Seeley, Ingrid Langsetmo Parobok
  • Pharmaceutical formulations of a HIF hydroxylase inhibitor
    Patent number: 10765672
    Abstract: The present disclosure relates to pharmaceutical formulations of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid and methods of use thereof.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: September 8, 2020
    Assignee: FibroGen, Inc.
    Inventors: David Conca, Lee Allen Flippin, Scott David Leigh, Claudia Witschi, Lee Robert Wright
  • Nitrogen-containing heteroaryl compounds and methods of use thereof
    Patent number: 10646482
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: May 12, 2020
    Assignee: FibroGen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 10626090
    Abstract: The present invention relates to methods and compounds for regulating or enhancing ethropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: April 21, 2020
    Assignee: FIBROGEN INC.
    Inventors: Stephen J. Klaus, Christopher J Molineaux, Thomas B Neff, Volkmar Guenzler-Pukall, Robert C. Stephenson, Todd W. Seeley, Ingrid Langsetmo Parobok
  • METHODS FOR TREATING IDIOPATHIC PULMONARY FIBROSIS
    Publication number: 20200113533
    Abstract: The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IPF) by administering anti-CTGF antibodies. Methods for prognosing individuals with IPF are also provided.
    Type: Application
    Filed: December 11, 2019
    Publication date: April 16, 2020
    Applicant: FibroGen, Inc.
    Inventors: Seth PORTER, John L. Stauffer
  • Methods for treating idiopathic pulmonary fibrosis
    Patent number: 10555713
    Abstract: The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IPF) by administering anti-CTGF antibodies. Methods for prognosing individuals with IPF are also provided.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: February 11, 2020
    Assignee: FIBROGEN, INC
    Inventors: Seth Porter, John L. Stauffer
  • METHODS OF TREATING IDIOPATHIC PULMONARY FIBROSIS
    Publication number: 20190127456
    Abstract: The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IPF) by administering an anti-CTGF antibody. In particular, the treatment methods provided avoid toxicities associated with approved therapies and also avoid the attenuation of the efficacy of an anti-CTGF antibody caused by these approved therapies.
    Type: Application
    Filed: September 14, 2018
    Publication date: May 2, 2019
    Applicant: FibroGen, Inc.
    Inventors: Seth Porter, Kenneth E. Lipson, Eduard Gorina de Travy, Kin-Hung Peony Yu
  • Crystalline forms of a prolyl hydroxylase inhibitor
    Patent number: 10272078
    Abstract: The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: April 30, 2019
    Assignee: FibroGen, Inc.
    Inventors: Claudia Witschi, Jung Min Park, Michael D. Thompson, Michael John Martinelli, David A. Yeowell, Michael P. Arend